Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Oct 4;91(7):1236-8.
doi: 10.1038/sj.bjc.6602152.

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

E Bromwich  1 , D C McMillan, G W A Lamb, P A Vasey, M Aitchison
Affiliations
Clinical Trial

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

E Bromwich et al. Br J Cancer. .

Abstract

The prognostic value of C-reactive protein, compared with ECOG performance status (ECOG-ps), in patients receiving alpha-interferon treatment for advanced renal cancer was assessed in 58 patients. In all, 55 patients died on follow-up. On multivariate analysis with ECOG-ps and C-reactive protein entered as covariates, only C-reactive protein was a significant independent predictor of survival (HR 2.03, 95% CI 1.09-3.80, P=0.026).

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) The relationship between C-reactive protein (⩽10 mgl−1 - - -, >10 mgl−1 __) and survival in patients receiving alpha-interferon treatment for advanced renal cancer. (B) The relationship between C-reactive protein (⩽50 mgl−1 - - -, >50 mgl−1 __) and survival in patients receiving alpha-interferon treatment for advanced renal cancer.
See this image and copyright information in PMC

References

    1. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634–1639 - PMC - PubMed
    1. Bennett M, Ryall N (2000) Using the modified Barthel index to estimate survival in cancer patients in hospice: observational study. BMJ 321(7273): 1381–1382 - PMC - PubMed
    1. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317–3322 - PubMed
    1. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89: 1028–1030 - PMC - PubMed
    1. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90: 1704–1706 - PMC - PubMed

Publication types

MeSH terms